Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Down 6.1 %

Shares of NASDAQ BCLI opened at $0.34 on Thursday. The company has a market cap of $23.72 million, a price-to-earnings ratio of -1.06 and a beta of 0.43. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $2.18. The stock has a 50-day moving average price of $0.46 and a two-hundred day moving average price of $0.41.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. On average, sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.